GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dogwood Therapeutics Inc (NAS:DWTX) » Definitions » Book Value per Share

DWTX (Dogwood Therapeutics) Book Value per Share : $2.82 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Dogwood Therapeutics Book Value per Share?

Dogwood Therapeutics's book value per share for the quarter that ended in Jun. 2024 was $2.82.

During the past 12 months, Dogwood Therapeutics's average Book Value Per Share Growth Rate was -55.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -62.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Dogwood Therapeutics was -62.00% per year. The lowest was -62.00% per year. And the median was -62.00% per year.

Dogwood Therapeutics's current price is $4.44. Its book value per share for the quarter that ended in Jun. 2024 was $2.82. Hence, today's PB Ratio of Dogwood Therapeutics is 1.57.

During the past 6 years, the highest P/B Ratio of Dogwood Therapeutics was 10.77. The lowest was 0.00. And the median was 0.00.


Dogwood Therapeutics Book Value per Share Historical Data

The historical data trend for Dogwood Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dogwood Therapeutics Book Value per Share Chart

Dogwood Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial -26.00 90.13 43.52 9.99 4.94

Dogwood Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.30 6.18 4.94 3.45 2.82

Competitive Comparison of Dogwood Therapeutics's Book Value per Share

For the Biotechnology subindustry, Dogwood Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dogwood Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dogwood Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Dogwood Therapeutics's PB Ratio falls into.



Dogwood Therapeutics Book Value per Share Calculation

Dogwood Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3.81-0.00)/0.77
=4.94

Dogwood Therapeutics's Book Value Per Share for the quarter that ended in Jun. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3.14-0.00)/1.11
=2.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Dogwood Therapeutics  (NAS:DWTX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Dogwood Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Dogwood Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Dogwood Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
44 Milton Avenue, Alpharetta, GA, USA, 30009
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ("FM") and Long-COVID ("LC"). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Executives
William Pridgen director 44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan director, officer: Chief Executive Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh officer: VP of Finance 44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel director 44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer director 44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald officer: Vice President of Operations 44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau officer: Chief Medical Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch director 44 MILTON AVENUE, ALPHARETTA GA 30009

Dogwood Therapeutics Headlines

From GuruFocus